Pharsight

1. Gralise patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP02781665A	2014-01-03	Purdue Pharma LP	Patent maintained as amended

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6635280	ALMATICA	Extending the duration of drug release within the stomach during the fed mode	Sep, 2016 (7 years ago)
US6340475	ALMATICA	Extending the duration of drug release within the stomach during the fed mode	Sep, 2016 (7 years ago)
US6488962	ALMATICA	Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms	Jun, 2020 (3 years ago)
US6723340	ALMATICA	Optimal polymer mixtures for gastric retentive tablets	Oct, 2021 (2 years ago)
US8252332	ALMATICA	Gastric retained gabapentin dosage form	Oct, 2022 (1 year, 6 months ago)
US8192756	ALMATICA	Gastric retained gabapentin dosage form	Oct, 2022 (1 year, 6 months ago)
US7731989	ALMATICA	Gastric retained gabapentin dosage form	Oct, 2022 (1 year, 6 months ago)
US8333992	ALMATICA	Gastric retained gabapentin dosage form	Oct, 2022 (1 year, 6 months ago)
US7438927	ALMATICA	Methods of treatment using a gastric retained gabapentin dosage	Feb, 2024 (a month ago)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE)	Jan 28, 2018
Orphan Drug Exclusivity(ODE-6)	Jan 28, 2018
New Product(NP)	Jan 28, 2014

Market Authorisation Date: 28 January, 2011

Treatment: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
300 mg and 600 mg	31 Oct, 2011	1		26 Feb, 2024

Strength	Dosage	Availability
300MG	TABLET;ORAL	Prescription
600MG	TABLET;ORAL	Prescription

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8999393	ALMATICA	Sustained release formulations of lorazepam	Jan, 2034 (9 years from now)

Market Authorisation Date: 27 August, 2021

Treatment: Once daily treatment of anxiety disorder in adults

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
1MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
3MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
1.5MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
2MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US7776358	December, 2008	Decision	Joan Cucala Escoi et al

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6717015	ALMATICA	Venlafaxine besylate	Mar, 2023 (1 year, 30 days ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7776358	ALMATICA	Extended release venlafaxine besylate tablets	May, 2028 (4 years from now)

Market Authorisation Date: 29 June, 2022

Treatment: Treatment of depression and generalized anxiety disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL